Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients.

@article{Nakashita2016PossibleEO,
  title={Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients.},
  author={Tamao Nakashita and Katsutoshi Ando and Kazuhisa Takahashi and Shinji Motojima},
  journal={Respiratory investigation},
  year={2016},
  volume={54 5},
  pages={
          376-9
        }
}
Rheumatoid arthritis (RA) is a generally progressive, systemic autoimmune condition characterized by chronic erosive synovitis. Interstitial lung disease (ILD) is a common extraarticular manifestation of RA and is substantially more likely to cause morbidity and mortality [1]. Several diseasemodifying anti-rheumatic drugs and numerous biological therapies for RA have been widely used. These treatments, targeted at alleviating symptoms and preventing joint destruction, represent an important… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Comorbidity in Rheumatic Diseases

  • Springer International Publishing
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES

Abatacept therapy in rheumatoid arthritis with interstitial lung disease.

  • Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • 2014
VIEW 1 EXCERPT